Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals Inc (NQ: ACXP )

1.350 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acurx Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Race To The Cure: Here’s Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff
C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United... 
Via TheNewswire.com
Topics Death
Exposures Death Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Acurx Pharmaceuticals Surges 29% In August, Here’s Why The ACXP Bulls Expect Much More To Come ($ACXP)
Via AB Newswire
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day... 
Via Benzinga
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP)
Via AB Newswire
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-... 
Via Benzinga
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
Via AB Newswire
If A Santa Claus Rally Comes To Town, Expect Acurx Pharmaceuticals To Be On The Lead Sleigh…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
With A Phase 2b Trial In Progress, Acurx Pharmaceuticals May be The Most Undervalued Biotech On The Market…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Stock Spikes 10% After Reaching Phase 2b Milestone Evaluating Ibezapolstat To Treat CDI (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP)
Via AB Newswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
Acurx Pharmaceuticals’ Drug Candidate Ibezapolstat Continues To Score Clinical Wins In Treating C. Difficile (NASDAQ: ACXP)
Via AB Newswire
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
VIDEO Report: Acurx Pharmaceuticals’ Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)
Via AB Newswire
CEO In Focus: Acurx Pharma CEO Confident His Company’s Phase 2b Ibezapolstat Trial Can Lead To A Front-Line Treatment For C. difficile (NASDAQ: ACXP)
Via AB Newswire
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing... 
Via Newsfile
Topics Death Derivatives Initial Public Offering
Exposures Death Derivatives Intellectual Property
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
Via AB Newswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.